Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre

被引:10
作者
Anastasiou, Christine [1 ]
Dulai, Olivia [2 ,3 ]
Baskaran, Amrutha [1 ]
Proudfoot, James [4 ]
Verhaegen, Samuel [4 ]
Kalunian, Kenneth [1 ]
机构
[1] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Dept Med, Med Ctr, La Jolla, CA 92093 USA
[3] Chadwick Sch, Palos Verdes Peninsula, CA USA
[4] Univ Calif San Diego, Clin & Translat Res Inst, La Jolla, CA 92093 USA
来源
LUPUS SCIENCE & MEDICINE | 2018年 / 5卷 / 01期
关键词
PREVALENCE; SURVIVAL; HYDROXYCHLOROQUINE; INFECTIONS; PREDICTORS; MORTALITY; LUMINA;
D O I
10.1136/lupus-2017-000249
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe how immunosuppressant use and hospitalisation patterns for SLE have evolved by comparing admission statistics at one academic centre between 2005 and 2013. Methods We identified admissions for SLE and for all hospitalised patients by using the hospital electronic database. For adult patients with SLE, a comprehensive chart review was conducted to identify primary indications for hospitalisation, in-hospital mortality, mean length of stay and immunosuppressant use. Results The number of yearly SLE patient hospitalisations decreased from 178 to 86 between the two times of observation. Infection was the most common reason for hospitalisation accounting for 39.9% of hospitalisations in 2005 versus 31.4% of hospitalisations in 2013 (p=0.29). Lupus flare accounted for 9.6% of admissions in 2005 versus 8.1% of admissions in 2013 (p=0.72). Seven patients died during their hospitalisation (3.9% of admissions) in 2005 as opposed to no inpatient deaths in 2013. Of the 261 admissions between 2010 and 2013, six admissions resulted in death (2.3% of admissions). SLE patient mean length of hospital stay decreased from 7.6 days to 6.4 days (p=0.36) compared with all patient length of stay, which decreased from 6 days to 5.8 days. Corticosteroid use decreased (79.8% to 61.6%, p=0.11) while hydroxychloroquine (27.0% to 59.3%, p<0.001) use increased over time. Conclusions The number of hospitalisations, mortality and length of stay among hospitalised patients with SLE decreased over time. Infection was the primary reason for inpatient hospitalisation. Hydroxychloroquine use more than doubled over this same time period with statistical significance. These pilot data suggest improvements in SLE hospitalisation outcomes over time, but larger studies are needed to examine these trends and to understand the relationship between changing medication prescribing patterns and hospitalisation outcomes in patients with SLE.
引用
收藏
页数:6
相关论文
共 24 条
[1]   Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus:: Data from LUMINA, a multiethnic US cohort (LUMINA L) [J].
Alarcon, Graciela S. ;
McGwin, Gerald ;
Bertoli, Ana M. ;
Fessler, Barri J. ;
Calvo-Alen, Jaime ;
Bastian, Holly M. ;
Vila, Luis M. ;
Reveille, John D. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) :1168-1172
[2]   Seizures in patients with systemic lupus erythematosus:: data from LUMINA, a multiethnic cohort (LUMINA LIV) [J].
Andrade, R. M. ;
Alarcon, G. S. ;
Gonzalez, L. A. ;
Fernandez, M. ;
Apte, M. ;
Vila, L. M. ;
McGwin, G., Jr. ;
Reveille, J. D. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (06) :829-834
[3]  
[Anonymous], ANN EST RES POP
[4]   Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data [J].
Chakravarty, Eliza F. ;
Bush, Thomas M. ;
Manzi, Susan ;
Clarke, Ann E. ;
Ward, Michael M. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (06) :2092-2094
[5]   Hydroxychloroquine in lupus pregnancy [J].
Clowse, Megan E. B. ;
Magder, Laurence ;
Witter, Frank ;
Petri, Michelle .
ARTHRITIS AND RHEUMATISM, 2006, 54 (11) :3640-3647
[6]  
DUFFY KNW, 1991, J RHEUMATOL, V18, P1180
[7]   Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome [J].
Edwards, CJ ;
Lian, TY ;
Badsha, H ;
Teh, CL ;
Arden, N ;
Chng, HH .
LUPUS, 2003, 12 (09) :672-676
[8]   Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis [J].
Ginzler, EM ;
Dooley, MA ;
Aranow, C ;
Kim, MY ;
Buyon, J ;
Merrill, JT ;
Petri, M ;
Gilkeson, GS ;
Wallace, DJ ;
Weisman, MH ;
Appel, GB .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) :2219-2228
[9]   Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011 (vol 10, e0128920, 2015) [J].
Goss, Louisa B. ;
Ortiz, Justin R. ;
Okamura, Daryl M. ;
Hayward, Kristen ;
Goss, Christopher H. .
PLOS ONE, 2015, 10 (10)
[10]   FATAL INFECTIONS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - THE ROLE OF OPPORTUNISTIC ORGANISMS [J].
HELLMANN, DB ;
PETRI, M ;
WHITINGOKEEFE, Q .
MEDICINE, 1987, 66 (05) :341-348